Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 44, Issue 5 (May 2006)

Issues

Evaluation of serum levels of p53 in hepatocellular carcinoma in Egypt

Mohamed A. El Far / Mohamed A. Atwa / Raida S. Yahya / Mohamed A. El Basuni
Published Online: 2006-05-08 | DOI: https://doi.org/10.1515/CCLM.2006.091

Abstract

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-induced death. Somatic mutation of the p53 gene is the most common genetic abnormality so far described in human cancer and there is evidence that supports a high level of p53 alterations in HCC. The aim of this study was to investigate serum levels of p53 in Egyptian patients with HCC, and its relation to other prognostic factors such as tumor grade, α-fetoprotein (AFP), and liver function tests in an attempt to clarify their significance in the pathogenesis of the disease. Liver function tests were carried out and AFP and p53 levels were measured for all individuals studied. Our results show that detection of p53 increased the frequency of HCC prediction from 79.5% to 86.3%. Moreover, significant positive correlation between p53 and tumor size (cm) for tumor grade II and III was identified. In conclusion, serum concentration of p53 protein may be a convenient and useful non-invasive screening test for prediction of HCC.

Keywords: α-fetoprotein; hepatitis B virus (HBV); hepatitis C virus (HCV); hepatocellular carcinoma; p53

References

  • 1.

    Vauthey JN. Hepatobiliary cancer. Cancer Control 1998; 5:32–3.Google Scholar

  • 2.

    Oka H, Kurioka N, Kim K, Kanno T, Kuroki K, Mizguchi Y, et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990; 12:680–7.CrossrefGoogle Scholar

  • 3.

    London TW. Hepatocellular carcinoma. Etiology and pathology. In: Proceedings of the ASCO 34th annual meeting, Los Angeles, CA, May 1998:168–75.Google Scholar

  • 4.

    Hsu YL, Kuo PL, Chiang LC, Lin CC. Involvement of p53, nuclear factor κB and Fas/Fas ligand in induction of apoptosis and cell cycle arrest by saikosaponin d in human hepatoma cell lines. Cancer Lett 2004; 213:213–21.CrossrefGoogle Scholar

  • 5.

    Volkmann M, Hofmann WJ, Muller M, Karth U, Otto G, Zentgraf H, et al. p53 over-expression is frequent in Europeans in hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene 1994; 9:195–204.Google Scholar

  • 6.

    Lui WY, Chiu ST, Chiu JH, Loong CC, Chau GY, King KL, et al. Evaluation of a simplified staging system for prognosis of hepatocellular carcinoma. J Formos Med Assoc 1999; 98:248–53.Google Scholar

  • 7.

    Peng SY, Chen WJ, Lai PL, Jeng YMS. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer 2004; 112:44–50.CrossrefGoogle Scholar

  • 8.

    Kannangai R, Wang J, Liu QZ, Sahin F, Torbenson M. Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation. Int J Gastrointest Cancer 2005; 35:53–60.CrossrefGoogle Scholar

  • 9.

    Reeves ME, De Matteo RB. Genes and viruses in hepatobiliary neoplasia. Semin Surg Oncol 2000; 19:84–93.CrossrefGoogle Scholar

  • 10.

    Okada T, Iizuka N, Yamada-Okabe H, Mori N, Tamesa T, Takemoto N, et al. Gene expression profile linked to p53 status in hepatitis C virus-related hepatocellular carcinoma. FEBS Lett 2003; 555:583–90.Google Scholar

  • 11.

    Cho JW, Park K, Kweon GR, Park JC, Lee JC, Baek WK, et al. Modulation of cell death sensitivity by mutant p53 in HCV core-expressing cells. Int J Mol Med 2005; 15:475–80.Google Scholar

  • 12.

    Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26(Suppl 1):345–85.Google Scholar

  • 13.

    Lin J, Zhu MH, Qu JH, Li FM, Ni CR. Effects of hepatitis B virus X gene on p21(WAF1) expression through p53-dependent and p53-independent pathways. Ai Zheng 2004; 23:749–55.Google Scholar

  • 14.

    Okada S, Sato T, Okusaka T, Ikeda M, Nakasuka H, Kosakamoto H, et al. Past exposure to hepatitis B virus as a risk factor for hepatocellular carcinoma in patients with chronic liver disease. Br J Cancer 1998; 77:2028–31.CrossrefGoogle Scholar

  • 15.

    Shieh YS, Nguyen C, Vocal MV, Chu H. Tumor suppressor p53 gene in hepatitis C and B virus associated human HCC. Int J Cancer 1993; 54:558–62.CrossrefGoogle Scholar

  • 16.

    Ray RB, Steele R, Meyer K, Ray R. Transcription repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 1997; 272:10983–6.Google Scholar

About the article

Corresponding author: Professor Mohamed A. El Far, Division of Biochemistry, Faculty of Sciences, Mansoura University, Mansoura, Egypt Phone: +20-10-1562520, Fax: +20-50-2246781,


Received: 2005-08-31

Accepted: 2006-02-06

Published Online: 2006-05-08

Published in Print: 2006-05-01


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2006.091.

Export Citation

©2006 by Walter de Gruyter Berlin New York. Copyright Clearance Center

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Mohammad Hasanzadeh and Nasrin Shadjou
Materials Science and Engineering: C, 2017, Volume 76, Page 1424
[2]
Mohammad Hasanzadeh, Nasrin Shadjou, and Miguel de la Guardia
TrAC Trends in Analytical Chemistry, 2017, Volume 89, Page 13
[3]
Sayeh Ezzikouri, Pascal Pineau, and Soumaya Benjelloun
Journal of Medical Virology, 2013, Volume 85, Number 9, Page 1542
[4]
Fabio Domenici, Anna Rita Bizzarri, and Salvatore Cannistraro
Analytical Biochemistry, 2012, Volume 421, Number 1, Page 9
[5]
Abdelfattah M. Attallah, Gamal E. Shiha, Hisham Ismail, Seham E. Mansy, Rania El-Sherbiny, and Ibrahim El-Dosoky
Clinical Biochemistry, 2009, Volume 42, Number 6, Page 455
[6]
Joana D. Amaral, Rui E. Castro, Clifford J. Steer, and Cecília M.P. Rodrigues
Trends in Molecular Medicine, 2009, Volume 15, Number 11, Page 531
[7]
Xuxian Xiao, Qiongqiong He, and Kelong Huang
Medical Oncology, 2010, Volume 27, Number 4, Page 1200
[8]
Min Wu, Chen Mao, Qing Chen, Xin-Wei Cu, and Wei-Seng Zhang
Molecular Biology Reports, 2010, Volume 37, Number 1, Page 339

Comments (0)

Please log in or register to comment.
Log in